| Added by | jacques.colinge |
|---|---|
| Group name | EquipeJC |
| Item Type | Journal Article |
| Title | Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models |
| Creator | Kawabata-Iwakawa et al. |
| Author | Reika Kawabata-Iwakawa |
| Author | Norihiro Iwasa |
| Author | Kenichi Satoh |
| Author | Jacques Colinge |
| Author | Muneaki Shimada |
| Author | Satoshi Takeuchi |
| Author | Hiroyuki Fujiwara |
| Author | Hidetaka Eguchi |
| Author | Tetsuro Oishi |
| Author | Toru Sugiyama |
| Author | Mitsuaki Suzuki |
| Author | Kosei Hasegawa |
| Author | Keiichi Fujiwara |
| Author | Masahiko Nishiyama |
| Abstract | BACKGROUND: Platinum/taxane (TC) chemotherapy with debulking surgery stays the mainstay of the treatment in ovarian cancer patients with peritoneal metastasis, and recently its novel modality, intraperitoneal carboplatin with dose-dense paclitaxel (ddTCip), was shown to have greater therapeutic impact. Nevertheless, the response varies among patients and consequent recurrence, or relapse often occurs. Discovery of therapeutic response predictor to ddTCip and/or TC therapy is eagerly awaited to improve the treatment outcome. METHODS: Using datasets in 76 participants in our ddTCip study and published databases on patients received TC therapy, we first validated a total of 75 previously suggested markers, sought out more active biomarkers through the association analyses of genome-wide transcriptome and genotyping data with progression-free survival (PFS) and adverse events, and then developed multiplex statistical prediction models for PFS and toxicity by mainly using multiple regression analysis and the classification and regression tree (CART) algorithm. RESULTS: The association analyses revealed that SPINK1 could be a possible biomarker of ddTCip efficacy, while ABCB1 rs1045642 and ERCC1 rs11615 would be a predictor of hematologic toxicity and peripheral neuropathy, respectively. Multiple regression analyses and CART algorithm finally provided a potent efficacy prediction model using 5 gene expression data and robust multiplex toxicity prediction models-CART models using a total of 4 genotype combinations and multiple regression models using 15 polymorphisms on 12 genes. CONCLUSION: Biomarkers and multiplex models composed here could work well in the response prediction of ddTCip and/or TC therapy, which might contribute to realize optimal selection of the key therapy. |
| Publication | International Journal of Clinical Oncology |
| Volume | 29 |
| Issue | 9 |
| Pages | 1334-1346 |
| Date | 2024-09 |
| Journal Abbr | Int J Clin Oncol |
| Language | eng |
| DOI | 10.1007/s10147-024-02552-w |
| ISSN | 1437-7772 |
| Short Title | Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors |
| Library Catalog | PubMed |
| Extra | PMID: 38767719 |
| Tags | Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, ATP Binding Cassette Transporter, Subfamily B, Biomarkers, Tumor, Carboplatin, Cytoreduction Surgical Procedures, DNA-Binding Proteins, Endonucleases, Female, First-line chemotherapy, Humans, Intraperitoneal carboplatin plus intravenous dose-dense paclitaxel (ddTCip) therapy, Middle Aged, original, Ovarian cancer, Ovarian Neoplasms, Paclitaxel, Peritoneal Neoplasms, Personalized medicine, Predictive biomarker of therapeutic response, Progression-Free Survival |
| Date Added | 2024/09/08 - 16:55:42 |
| Date Modified | 2024/09/08 - 17:00:55 |
| Notes and Attachments | PubMed entry (Attachment) Submitted Version (Attachment) |
Institut de Recherche en Cancérologie de
